FGEN Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -1221.75% compared to FibroGen, Inc.'s net margin of -12425.36%. FibroGen, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

FibroGen, Inc. has a consensus price target of $43.00, signalling upside risk potential of 400.87%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that FibroGen, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe FibroGen, Inc. is more attractive than Perspective Therapeutics, Inc..

FibroGen, Inc. has a beta of 0.747, which suggesting that the stock is 25.347% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

FibroGen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

FibroGen, Inc. quarterly revenues are $1.1M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. FibroGen, Inc.'s net income of -$13.1M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, FibroGen, Inc.'s price-to-earnings ratio is 0.22x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen, Inc. is 29.24x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -1221.75% compared to FibroGen, Inc.'s net margin of -36.3%. FibroGen, Inc.'s return on equity of -- beat Myomo, Inc.'s return on equity of -68.35%.

FibroGen, Inc. has a consensus price target of $43.00, signalling upside risk potential of 400.87%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that FibroGen, Inc. has higher upside potential than Myomo, Inc., analysts believe FibroGen, Inc. is more attractive than Myomo, Inc..

FibroGen, Inc. has a beta of 0.747, which suggesting that the stock is 25.347% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

FibroGen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

FibroGen, Inc. quarterly revenues are $1.1M, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. FibroGen, Inc.'s net income of -$13.1M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, FibroGen, Inc.'s price-to-earnings ratio is 0.22x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen, Inc. is 29.24x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience, Inc. has a net margin of -1221.75% compared to FibroGen, Inc.'s net margin of --. FibroGen, Inc.'s return on equity of -- beat Skye Bioscience, Inc.'s return on equity of -91.57%.

FibroGen, Inc. has a consensus price target of $43.00, signalling upside risk potential of 400.87%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 888.73%. Given that Skye Bioscience, Inc. has higher upside potential than FibroGen, Inc., analysts believe Skye Bioscience, Inc. is more attractive than FibroGen, Inc..

FibroGen, Inc. has a beta of 0.747, which suggesting that the stock is 25.347% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.676, suggesting its more volatile than the S&P 500 by 167.642%.

FibroGen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.

FibroGen, Inc. quarterly revenues are $1.1M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. FibroGen, Inc.'s net income of -$13.1M is lower than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, FibroGen, Inc.'s price-to-earnings ratio is 0.22x while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen, Inc. is 29.24x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of -1221.75% compared to FibroGen, Inc.'s net margin of 18.08%. FibroGen, Inc.'s return on equity of -- beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

FibroGen, Inc. has a consensus price target of $43.00, signalling upside risk potential of 400.87%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 42.63%. Given that FibroGen, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe FibroGen, Inc. is more attractive than Theravance Biopharma, Inc..

FibroGen, Inc. has a beta of 0.747, which suggesting that the stock is 25.347% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

FibroGen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

FibroGen, Inc. quarterly revenues are $1.1M, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. FibroGen, Inc.'s net income of -$13.1M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, FibroGen, Inc.'s price-to-earnings ratio is 0.22x while Theravance Biopharma, Inc.'s PE ratio is 33.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen, Inc. is 29.24x versus 11.75x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.